← Back to Analyst Consensus 
ABOS Buy
Acumen Pharmaceuticals, Inc.
Current Price —
Implied Upside —
Analysts 12
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 16, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Sep 15, 2026 | Citigroup | maintain | Buy → Buy | $5 | 54% |
| Mar 26, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Mar 16, 2026 | BTIG | maintain | Buy → Buy | $8 | 52% |
| Jan 27, 2026 | BTIG | maintain | Buy → Buy | $7 | 52% |
| Nov 18, 2025 | B of A Securities | maintain | Buy → Buy | $8 | 53% |
| Aug 25, 2025 | B of A Securities | maintain | Buy → Buy | $9 | 53% |
| Jun 17, 2025 | Citigroup | initiate | — → Buy | $4 | 54% |
| Mar 28, 2025 | UBS | maintain | Buy → Buy | $4 | 54% |
| Mar 28, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $11 | 44% |
| Nov 13, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| Oct 3, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| Aug 15, 2024 | UBS | maintain | Buy → Buy | $6 | 54% |
| Aug 14, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| Jul 25, 2024 | Citigroup | initiate | — → Buy | $7 | 54% |
| May 15, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| Mar 31, 2024 | UBS | maintain | Buy → Buy | $14 | 54% |
| Mar 27, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $15 | 44% |
| Dec 12, 2023 | Deutsche Bank | initiate | — → Buy | $8 | 57% |
| Aug 9, 2023 | Credit Suisse | reiterate | Outperform → Outperform | $13 | — |
| Aug 9, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| Jul 17, 2023 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $13 | 50% |
| Jul 17, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| May 18, 2023 | Cantor Fitzgerald | initiate | — → Overweight | $13 | 50% |
| Mar 28, 2023 | Credit Suisse | maintain | — → Outperform | $13 | — |
| Mar 28, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $15 | 44% |
| Feb 2, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $15 | 44% |
| Nov 15, 2022 | Credit Suisse | maintain | — → Outperform | $16 | — |
| Oct 5, 2022 | BTIG | maintain | — → Buy | $22 | 52% |
| Jul 15, 2022 | BTIG | initiate | — → Buy | $15 | 52% |
| Jun 30, 2022 | HC Wainwright & Co. | initiate | — → Buy | $15 | 44% |
| Mar 29, 2022 | Credit Suisse | maintain | — → Outperform | $17 | — |
| Jan 21, 2022 | B of A Securities | upgrade | Neutral → Buy | $14 | 53% |
| Jul 26, 2021 | UBS | initiate | — → Buy | $27 | 54% |
| Jul 26, 2021 | B of A Securities | initiate | — → Neutral | $20 | 53% |
| Jul 26, 2021 | Credit Suisse | initiate | — → Outperform | $26 | — |
| Jul 26, 2021 | Stifel | initiate | — → Buy | $27 | 53% |
Price Target Trend
Mar 26, 2026 Oct 26, 2026
EPS Estimates
0q —
+1q —
0y —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days